Perspective Therapeutics (CATX) Competitors

Perspective Therapeutics (NYSE:CATX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Do analysts rate CATX or EMBC?

Perspective Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 398.01%. Embecta has a consensus price target of $20.33, indicating a potential upside of 93.47%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Perspective Therapeutics is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.18
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Is CATX or EMBC more profitable?

Embecta has a net margin of 5.25% compared to Perspective Therapeutics' net margin of -4,096.66%. Embecta's return on equity of -19.22% beat Perspective Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Embecta	5.25%	-19.22%	11.92%

Does the MarketBeat Community believe in CATX or EMBC?

Perspective Therapeutics received 33 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 97.22% of users gave Perspective Therapeutics an outperform vote while only 10.53% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
Perspective Therapeutics	Outperform Votes 35 97.22%	Underperform Votes 1 2.78%
Embecta	Outperform Votes 2 10.53%	Underperform Votes 17 89.47%

Which has more volatility & risk, CATX or EMBC?

Perspective Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in CATX or EMBC?

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 0.4% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has higher valuation & earnings, CATX or EMBC?

Embecta has higher revenue and earnings than Perspective Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43M	130.29	-$46.51M	N/A	N/A
Embecta	$1.08B	0.57	$78.30M	$0.90	11.68

Does the media refer more to CATX or EMBC?

In the previous week, Perspective Therapeutics had 14 more articles in the media than Embecta. MarketBeat recorded 17 mentions for Perspective Therapeutics and 3 mentions for Embecta. Embecta's average media sentiment score of 1.03 beat Perspective Therapeutics' score of 0.90 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perspective Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Perspective Therapeutics beats Embecta on 9 of the 17 factors compared between the two stocks.